On January 22, 2021, the FDA approved a supplemental application for Opdivo (nivolumab), specifically for efficacy. This approval was granted to sponsor Bristol Myers Squibb.
Background
Opdivo (nivolumab) is a pharmaceutical product developed by Bristol Myers Squibb. This supplemental approval pertains to its efficacy, indicating that new data supported an expanded or modified use of the drug. Supplemental applications for efficacy are typically submitted to extend a drug's approved indications, modify dosing, or expand the patient population for which the drug is approved.
What this means
The FDA's supplemental approval for Opdivo (nivolumab) for efficacy signifies that the agency has reviewed and accepted new clinical data demonstrating a beneficial effect of the drug. While the specific new indication, patient population, or other details of this efficacy approval are not provided in the source information, such approvals generally expand the therapeutic options available to clinicians and patients. This allows for broader application of Opdivo in clinical practice based on new evidence of its effectiveness.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125554 S-90 was posted on January 22, 2021, on accessdata.fda.gov.